Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cibus ( (CBUS) ) has shared an update.
On March 25, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 6,976,744 shares of its Class A common stock at $2.15 per share, with a 30-day option for the underwriter to purchase up to 1,046,511 additional shares. The offering, expected to close around March 27, 2026, is anticipated to generate approximately $13.5 million in net proceeds, or up to $16.0 million if the option is fully exercised, after underwriting discounts and expenses.
Under the agreement, BTIG will receive a 7.0% underwriting discount on gross proceeds and reimbursement of up to $150,000 in documented expenses, while Cibus has provided customary indemnification against certain Securities Act liabilities. The company, along with its directors and executive officers, also agreed to a 60-day lock-up on sales or transfers of Class A common stock without the underwriter’s consent, signaling a temporary restriction on insider share sales following the capital raise.
The most recent analyst rating on (CBUS) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
Spark’s Take on CBUS Stock
According to Spark, TipRanks’ AI Analyst, CBUS is a Neutral.
The score is held down primarily by weak financial performance (large losses, sustained cash burn, and sharply reduced equity base). Technical indicators also show negative near-term momentum. Offsetting factors come from the earnings call, which pointed to improving execution (cost cuts, financing) and multiple regulatory/commercial catalysts, but near-term funding and profitability risks remain.
To see Spark’s full report on CBUS stock, click here.
More about Cibus
Cibus, Inc. operates in the biotechnology and agricultural technology sector, focusing on crop genetics and seed trait development for agricultural markets. The company develops and commercializes gene-edited traits aimed at improving crop performance, positioning itself within the broader agtech and sustainable agriculture industry.
Average Trading Volume: 513,259
Technical Sentiment Signal: Sell
Current Market Cap: $147.4M
For detailed information about CBUS stock, go to TipRanks’ Stock Analysis page.